CORDIS
EU research results

CORDIS

English EN
GALAXY: Gut-and-liver axis in alcoholic liver fibrosis

GALAXY: Gut-and-liver axis in alcoholic liver fibrosis

Objective

Alcohol overuse is an important societal challenge with annual healthcare costs of over €22 billion in Europe. Alcohol is the main cause of liver cirrhosis, which is the 5th and 7th most common cause of life years lost in respectively Eastern and Western Europe. Cirrhosis is considered irreversible but its precursor, liver fibrosis, is reversible when detected before disease progression. GALAXY proposes that crosstalk between the gut microbiome and the liver influences the development and progression of alcoholic liver fibrosis. Here, a ‘dysbiotic’ microbiome in susceptible individuals leads to progressive liver fibrosis in combination with alcohol overuse. Therefore, interventions aiming to restore a healthy gut microbiome will reduce disease development. We will use state-of-the-art systems medicine tools to improve understanding of the complex interplay present during alcoholic liver fibrosis, to identify at-risk individuals in time and to develop personalised healthcare strategies for alcohol over-users (20% of the EU population >15 years old). GALAXY brings together partners with unique research competences in clinical hepatology, microbiome, multi-omics, biomarkers and bioinformatics. Our aim is to develop novel systems medicine tools which integrate clinical, multi-omics and lifestyle information from alcohol over-users at various stages of the disease and healthy individuals in order to: 1) identify signatures of host-microbial cross-talk during disease development and progression, 2) translate this into biomarkers for diagnosis, stratification and treatment monitoring in alcohol over users, and 3) evaluate new interventions to modulate gut microbiota towards prevention and mitigation of the disease in at-risk individuals. We will also study societal and economic impact of GALAXY biomarkers and treatments to accelerate future development. The GALAXY consortium includes strong SME partners who will enable the results to be exploited commercially.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

SYDDANSK UNIVERSITET

Address

Campusvej 55
5230 Odense M

Denmark

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 639 843

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

EUROPEAN MOLECULAR BIOLOGY LABORATORY

Germany

EU Contribution

€ 1 387 000

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 928 752

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON

Greece

EU Contribution

€ 427 987

UNIVERSITAETSKLINIKUM BONN

Germany

EU Contribution

€ 353 240,87

Steno Diabetes Center A/S

Denmark

EU Contribution

€ 130 279,24

NORDIC BIOSCIENCE A/S

Denmark

EU Contribution

€ 301 381

NORDIC BIOSCIENCE COMPOUND DEVELOPMENT A/S

Denmark

NORDISK REBALANCE AS

Denmark

EU Contribution

€ 178 907

UNIVERSITETET I OSLO

Norway

EU Contribution

€ 195 127

ODENSE UNIVERSITETSHOSPITAL

Denmark

EU Contribution

€ 1 187 082

NORGINE BV

Netherlands

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 328 685,76

JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN

Germany

EU Contribution

€ 247 369,13

Project information

Grant agreement ID: 668031

Status

Ongoing project

  • Start date

    1 January 2016

  • End date

    31 December 2021

Funded under:

H2020-EU.3.1.1.

  • Overall budget:

    € 6 408 782,51

  • EU contribution

    € 6 305 654

Coordinated by:

SYDDANSK UNIVERSITET

Denmark